TY - JOUR
TI - The role of host immune response and apoptosis in patients with
laryngeal squamous cell carcinoma
AU - Gomatos, I. P.
AU - Georgiou, A.
AU - Giotakis, J.
AU - Manolopoulos, L.
AU - and Apostolou, K.
AU - Chatzigianni, E.
AU - Albanopoulos, K. and
AU - Ferekidou, E.
JO - ORL:  Journal for Oto - Rhino - Laryngology and Its Related Specialties
PY - 2007
VL - 69
TODO - 3
SP - 159-166
PB - Karger
SN - 1423-0275
TODO - 10.1159/000099225
TODO - bax; bcl-2; HLA-DR; laryngeal cancer
TODO - Purpose: To determine whether the combined use of markers of host immune
response (HLA-DR) and apoptosis (bax and bcl-2) can predict prognosis in
laryngeal carcinoma patients. Procedures: Immunohistochemical staining
for HLA-DR, bax and bcl-2 proteins was investigated retrospectively in
37 patients with laryngeal squamous cell carcinoma. Seven healthy adult
males were used as the control group. Results: HLA-DR antigen expression
was detected in the tumor cells of 18 patients (48.6%). Another 18
patients (48.6%) expressed HLA-DR antigen in the peritumoral
inflammatory infiltrate, while bax and bcl-2 protein expressions were
detected in 17 (45.9%) and 9 (24.3%) patients, respectively. None of
the controls expressed any of the proteins studied. bcl-2 and HLA-DR
protein expressions of the tumor infiltrate were statistically
significant independent prognostic factors suggesting improved survival
(p = 0.0272 and p = 0.0285, respectively). bax+/bcl-2- patients
demonstrated an unfavorable clinical outcome (p = 0.0298), followed by a
significantly increased mean HLA-DR antigen expression observed both in
the tumor and the stroma cells (p = 0.024 and p = 0.045, respectively).
Conclusions: bcl-2 and HLA-DR proteins independently predict a dismal
prognosis among laryngeal carcinoma patients. The bax+/bcl-2- protein
coexpression pattern correlates with elevated immunohistochemical
expression of HLA-DR antigen both by tumor and peritumoral stromal
cells. Message: bcl-2 and HLA-DR are significant prognostic markers in
laryngeal carcinoma patients. Further prospective investigation is
required to validate our findings. Copyright (c) 2007 S. Karger AG,
Basel.
ER -